Andrew Reardon
Equibles does not estimate personal net worth.
Get an email with a short summary when Ligand Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get LGND alertsAbout Andrew Reardon
The proxy statement of Ligand Pharmaceuticals Inc reports total compensation of $3,747,282 for Andrew Reardon in fiscal 2025, including a base salary of $476,675. Disclosed compensation is on record for 4 fiscal years. Ligand Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ligand Pharmaceuticals Inc includes Todd C. Davis (CEO and Board Member), Tavo Espinoza (CFO), Jason Haas (Board Member) and 7 others.
Affiliation history
-
Ligand Pharmaceuticals Inc (LGND)
Proxy statement
CurrentStart not stated–present
Last confirmed April 21, 2026
Company network
Leadership on record at Ligand Pharmaceuticals Inc
- Todd C. Davis CEO, Board Member
- Tavo Espinoza CFO
- Jason Haas Board Member
- Jason M. Aryeh Board Member
- Jennifer Cochran, Ph.D. Board Member
- John L. LaMattina Board Member
- John L. LaMattina, Ph.D. Board Member
- John W. Kozarich Board Member
- John W. Kozarich, Ph.D. Board Member
- Martine Zimmermann Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Ligand Pharmaceuticals Inc (LGND) | Chief Legal Officer and Secretary | $476,675 | $3,747,282 |
| 2024 | Ligand Pharmaceuticals Inc (LGND) | Chief Legal Officer and Secretary | $451,950 | $3,270,956 |
| 2023 | Ligand Pharmaceuticals Inc (LGND) | Chief Legal Officer and Secretary | $434,262 | $2,337,081 |
| 2022 | Ligand Pharmaceuticals Inc (LGND) | Chief Legal Officer and Secretary | $172,917 | $3,007,654 |
Recent activity
No call appearances or filed executive changes recorded yet.